skip to Main Content

Alimera at a glance.

Early Days

Alimera was founded in 2003, just outside Atlanta, by four former CIBA Vision employees who wanted to help patients see better while they themselves could live and raise their families in one of the fastest growing and dynamic cities in the country.

We developed two products; Soothe® Lubricant Eye Drops and Alaway® Antihistamine Eye Drops. We gained distribution in the United States and educated physicians on the unique benefits of Soothe and had Alaway approved by the FDA through a 505(b)(2) pathway. We then sold both products to Bausch and Lomb by 2007 to focus on development of ILUVIEN®.

ILUVIEN® is an intravitreal (back of the eye) implant that provides a therapeutic effect for up to 36 months by delivering sustained sub-microgram levels of fluocinolone acetonide. To learn more, please visit iluvien.com.

Going Public

In 2010, we became a public company, listed in the NASDAQ exchange under the ticker symbol ALIM.

Recent Expansion

In 2013, we established our European headquarters outside of London.  We also launched ILUVIEN in Europe for vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. Today we have Alimera offices in Aldershot, England; Dublin, Ireland; Berlin, Germany and Lisbon, Portugal.

In 2015, we launched ILUVIEN in the United States for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP). See ILUVIEN USA for details.

We have also expanded our distribution into France, Spain, Italy, the UAE and have approval for DME in Canada and Australia as well as in Belgium, Luxembourg and the Netherlands, all through our distributor partners.

We added a new indication for ILUVIEN in Europe and the Middle East in 2019; for the prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. See ILUVIEN EU for details.

Looking Forward

We always look forward.

We’re dedicated to commercializing and developing innovative, vision improving treatments for diseases of the retina and are always looking forward to helping patients see better longer, every day.

Back To Top
Skip to content